Correlation Between Truecaller and Lipigon Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Truecaller and Lipigon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Truecaller and Lipigon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Truecaller AB and Lipigon Pharmaceuticals AB, you can compare the effects of market volatilities on Truecaller and Lipigon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Truecaller with a short position of Lipigon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Truecaller and Lipigon Pharmaceuticals.

Diversification Opportunities for Truecaller and Lipigon Pharmaceuticals

-0.84
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Truecaller and Lipigon is -0.84. Overlapping area represents the amount of risk that can be diversified away by holding Truecaller AB and Lipigon Pharmaceuticals AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipigon Pharmaceuticals and Truecaller is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Truecaller AB are associated (or correlated) with Lipigon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipigon Pharmaceuticals has no effect on the direction of Truecaller i.e., Truecaller and Lipigon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Truecaller and Lipigon Pharmaceuticals

Assuming the 90 days trading horizon Truecaller AB is expected to generate 0.33 times more return on investment than Lipigon Pharmaceuticals. However, Truecaller AB is 3.05 times less risky than Lipigon Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Lipigon Pharmaceuticals AB is currently generating about -0.02 per unit of risk. If you would invest  4,824  in Truecaller AB on August 30, 2024 and sell it today you would lose (26.00) from holding Truecaller AB or give up 0.54% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Truecaller AB  vs.  Lipigon Pharmaceuticals AB

 Performance 
       Timeline  
Truecaller AB 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Truecaller AB are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Truecaller sustained solid returns over the last few months and may actually be approaching a breakup point.
Lipigon Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lipigon Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Truecaller and Lipigon Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Truecaller and Lipigon Pharmaceuticals

The main advantage of trading using opposite Truecaller and Lipigon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Truecaller position performs unexpectedly, Lipigon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipigon Pharmaceuticals will offset losses from the drop in Lipigon Pharmaceuticals' long position.
The idea behind Truecaller AB and Lipigon Pharmaceuticals AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets